Ocular Therapeutix Inc represents values of innovation, patient-centricity, and collaboration. With a focus on developing and commercializing cutting-edge therapies for eye conditions, the company strives to improve patient outcomes and enhance quality of life. Ocular Therapeutix Inc values scientific excellence and continuously seeks to advance in ocular drug delivery platforms. With a commitment to addressing unmet medical needs in ophthalmology, the company fosters partnerships and collaborations with experts and researchers. Through its dedication to breakthrough solutions and a patient-centered approach, Ocular Therapeutix Inc aims to revolutionize treatment options for ocular diseases and positively impact the lives of those affected.

Ocular Therapeutix Inc is primarily present in the United States, with headquarters located in Bedford, Massachusetts. As a biopharmaceutical company, Ocular Therapeutix focuses on developing and commercializing innovative therapies for eye diseases and conditions. With its strong presence in the United States, the company strives to provide effective and advanced ocular treatment options to patients in this region.

Ocular Therapeutix Inc, a renowned pharmaceutical company, has achieved significant milestones in its journey. The company has successfully developed innovative therapeutic ocular products aimed at improving patients' lives. Notably, Ocular Therapeutix received FDA approval for its product, DEXTENZA®, a sustained-release intracanalicular insert used in treating postoperative ocular pain. This milestone has solidified its position as a leader in the ophthalmic pharmaceutical industry. Additionally, the company has made remarkable progress in the field of glaucoma treatment, with their pipeline product OTX-TP, a sustained-release travoprost intracanalicular insert. Ocular Therapeutix continues to spearhead advancements in ocular healthcare, making it a promising name to watch in the stock market.

Ocular Therapeutix Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies for eye conditions. Founded in 2006, the company is headquartered in Bedford, Massachusetts. With a focus on sustained-release drug delivery technology, Ocular Therapeutix aims to provide patients with long-term treatment options for various ocular diseases. The company's portfolio includes products targeting drug delivery to the surface of the eye and the posterior segment. By continuously advancing research and collaboration efforts, Ocular Therapeutix Inc strives to improve the lives of individuals suffering from eye-related ailments.

The main competitors of Ocular Therapeutix Inc in the market include pharmaceutical companies such as Allergan, Novartis, and Alcon.

Ocular Therapeutix Inc is primarily active in the pharmaceutical and healthcare industries.

Ocular Therapeutix Inc. is a pharmaceutical company specializing in developing and commercializing innovative therapies for diseases and conditions affecting the eyes. Their business model revolves around the research, development, and commercialization of sustained-release drug delivery platforms for ophthalmic conditions and diseases. Ocular Therapeutix Inc. aims to improve patient outcomes by providing sustained drug delivery solutions that eliminate the need for frequent dosing and enhance therapeutic efficacy. Through their continuous efforts in developing novel therapies, Ocular Therapeutix Inc. strives to address unmet medical needs and improve the quality of life for patients dealing with various eye conditions.

Ocular Therapeutix KGV ir -3,82.

Ocular Therapeutix KUV ir 10,56.

AlleAktien kvalitātes vērtējums Ocular Therapeutix ir 6/10.

gaidāmā Ocular Therapeutix apgrozījums ir 67,50 milj. USD.

gaidāmā Ocular Therapeutix peļņa ir -186,67 milj. USD.

Ocular Therapeutix Inc is a biotechnology company focused on the development of innovative drugs and medical devices for ophthalmology. The company's business model is centered around advancing the development of new therapeutic options to help patients and physicians worldwide, specifically in the treatment of eye diseases. The company has two main areas of focus: the development of drugs for the treatment of eye diseases and the manufacturing of medical devices. Ocular has developed a wide range of solutions, ranging from ocular inserts to specialized lenses. This article will explain these areas in detail: Drugs for the treatment of eye diseases: Ocular Therapeutix has multiple product candidates in the pipeline targeting different eye diseases. The first candidate is DEXTENZA, a steroid eye implant developed for the treatment of pain and inflammation after eye surgeries. DEXTENZA has been FDA-approved and has been on the market since 2019. Additionally, Ocular Therapeutix is working on the development of drugs for the treatment of syndromes such as glaucoma and dry eye. Medical devices: Ocular Therapeutix is also involved in the development and manufacturing of medical devices targeting the treatment of eye diseases. The company has developed the OCUSERT® Punctal Plug System, a unique solution for the treatment of dry eye. The OCUSERT is a silicone plug inserted into the tear duct of the lower eyelid, improving tear flow. By using this solution, patients can better control their eye disease and minimize symptoms such as dryness and irritation. In addition to the OCUSERT, Ocular also offers a range of ocular insert products to support patients in the treatment of eye infections and diseases. These inserts are filled with special gel-like substances that gently cover the skin, providing pain relief and anti-inflammatory effects. Conclusion: Ocular Therapeutix has a strong business model focused on the development of innovative drugs and medical devices for ophthalmology. Through the production of drugs like DEXTENZA and the use of medical devices like the OCUSERT, the company will be able to improve the quality of life for millions of patients worldwide. With a strong R&D team and close partnerships with medical institutions around the world, Ocular Therapeutix is well-positioned to further expand its market leadership.

Ocular Therapeutix izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Ocular Therapeutix vai uzņēmums nedod dividendes.

Ocular Therapeutix ISIN ir US67576A1007.

Ocular Therapeutix WKN ir A1180P.

Ocular Therapeutix simbols ir OCUL.

Pēdējo 12 mēnešu laikā Ocular Therapeutix maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Ocular Therapeutix plāno maksāt dividendes 0 USD apmērā.

Ocular Therapeutix pašreizējā dividendu rentabilitāte ir .

Ocular Therapeutix maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Ocular Therapeutix pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Ocular Therapeutix tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Ocular Therapeutix apmērā 0 USD, kas tika izmaksāta 17.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 17.09.2024..

Pēdējās dividendes izmaksa notika 17.09.2024..

Gadā 2023, Ocular Therapeutix izmaksāja 0 USD dividendes.

Ocular Therapeutix dividendes tiek izmaksātas USD.